TY - JOUR

T1 - Базисная терапия при хронических неинфекционных дерматозах аногенитальной области

AU - Smirnova, I.O.

AU - Smirnova, O.N.

AU - Fedorova, I.A.

AU - Ptashnikova, P.D.

N1 - Export Date: 05 February 2026; Cited By: 0; Correspondence Address: I.O. Smirnova; St Petersburg State University, St Petersburg, 8а, 21st Liniya Vasilevskogo Ostrova St., 199106, Russian Federation; email: driosmirnova@yandex.ru

PY - 2025

Y1 - 2025

N2 - Chronic non-infectious dermatoses of the anogenital area comprise a heterogeneous group of diseases characterized by varied etiopathogenesis, clinical manifestations, disease course, and prognosis. Treatment of dermatological conditions in the anogenital area often presents a complex challenge and necessitates an interdisciplinary approach. Traditionally, comprehensive therapy is employed, including agents aimed at restoring the cutaneous barrier, topical anti-inflammatory medications, particularly glucocorticosteroids and/or topical calcineurin inhibitors, and less frequently, systemic glucocorticosteroids, retinoids, hydroxychloroquine, or dapsone, as well as interventions targeting the alleviation of subjective symptoms and the prevention and treatment of secondary infections. The purpose of this publication is to discuss the fundamental aspects of baseline therapy for chronic non-infectious dermatoses of anogenital area. Baseline therapy is defined as a set of interventions that a patient with a dermatosis receives over a prolonged or continuous period, even during disease remission. Approaches to baseline therapy for dermatoses of anogenital area are poorly developed and require further clarification. Nevertheless, the regulation of the spectrum and quantity of agents used by the patient on the genital and perianal areas, the elimination of irritants, normalization of daily hygiene practices, and the use of agents that restore the cutaneous barrier are crucial components of comprehensive therapy for skin diseases in this anatomical location. One of the key aspects of successful treatment of dermatoses of anogenital area is the restoration of the cutaneous barrier, which can be disrupted by both the underlying disease processes and exposure to external factors. This article details the effects of preparations based on 5% dexpanthenol, which is regarded as a moisturizing and wound-healing agent. Dexpanthenol demonstrates significant anti-inflammatory activity, comparable to that of corticosteroids. Its use in therapy not only improves skin condition but also enhances the efficacy of cjrticosteroids, which is particularly important for patients requiring long-term management of dermatoses. © 2025 Remedium Group Ltd. All rights reserved.

AB - Chronic non-infectious dermatoses of the anogenital area comprise a heterogeneous group of diseases characterized by varied etiopathogenesis, clinical manifestations, disease course, and prognosis. Treatment of dermatological conditions in the anogenital area often presents a complex challenge and necessitates an interdisciplinary approach. Traditionally, comprehensive therapy is employed, including agents aimed at restoring the cutaneous barrier, topical anti-inflammatory medications, particularly glucocorticosteroids and/or topical calcineurin inhibitors, and less frequently, systemic glucocorticosteroids, retinoids, hydroxychloroquine, or dapsone, as well as interventions targeting the alleviation of subjective symptoms and the prevention and treatment of secondary infections. The purpose of this publication is to discuss the fundamental aspects of baseline therapy for chronic non-infectious dermatoses of anogenital area. Baseline therapy is defined as a set of interventions that a patient with a dermatosis receives over a prolonged or continuous period, even during disease remission. Approaches to baseline therapy for dermatoses of anogenital area are poorly developed and require further clarification. Nevertheless, the regulation of the spectrum and quantity of agents used by the patient on the genital and perianal areas, the elimination of irritants, normalization of daily hygiene practices, and the use of agents that restore the cutaneous barrier are crucial components of comprehensive therapy for skin diseases in this anatomical location. One of the key aspects of successful treatment of dermatoses of anogenital area is the restoration of the cutaneous barrier, which can be disrupted by both the underlying disease processes and exposure to external factors. This article details the effects of preparations based on 5% dexpanthenol, which is regarded as a moisturizing and wound-healing agent. Dexpanthenol demonstrates significant anti-inflammatory activity, comparable to that of corticosteroids. Its use in therapy not only improves skin condition but also enhances the efficacy of cjrticosteroids, which is particularly important for patients requiring long-term management of dermatoses. © 2025 Remedium Group Ltd. All rights reserved.

KW - anti-inflammatory effect

KW - baseline therapy

KW - chronic dermatoses; anogenital region

KW - clinical manifestations

KW - dexpanthenol

KW - glucocorticosteroids

KW - pruritus

KW - skin barrier

KW - treatment

U2 - 10.21518/ms2025-146

DO - 10.21518/ms2025-146

M3 - статья

VL - 19

SP - 53

EP - 58

JO - МЕДИЦИНСКИЙ СОВЕТ

JF - МЕДИЦИНСКИЙ СОВЕТ

SN - 2079-7028

IS - 4

ER -